Current role
Todd Carter, Ph.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Todd Carter, Ph.D.
Voyager Therapeutics, Inc. reported in an 8-K filed September 7, 2022 that Todd Carter, Ph.D. was appointed Chief Scientific Officer, effective September 19, 2022.
“the Executive will be promoted to, and his title modified to, the position of Chief Scientific Officer as of September 19, 2022.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2022-09-19–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Voyager Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Alfred Sandrock CEO, Board Member
- Alfred Sandrock, M.D., Ph.D. CEO, Board Member
- Michael Higgins CEO, Board Member
- Nathan Jorgensen, Ph.D., M.B.A. CFO
- Peter P. Pfreundschuh CFO
- Robin Swartz CFO, COO
- Glenn Pierce, M.D., Ph.D. CTO, Board Member
- Gregory Shiferman General Counsel
- Amy Quinlan Chief Accounting Officer
- Julie Burek Chief Accounting Officer
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.